Moleculin Biotech, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $MBRX in the last 30 days.
See all $MBRX insider activity →Myriad Genetics (MYGN) surged 40% after agreeing to sell its Prenatal Health business to Labcorp for $210M. Moleculin Biotech (MBRX) rose 15% on AML trial progress. Femasys (FEMY) and Revolution Medicines (RVMD) each gained 7% on commercial and clinical developments.
Moleculin Biotech (MBRX) released a CEO Corner segment discussing progress in its Phase 2/3 MIRACLE trial for Annamycin in treating relapsed or refractory AML. Enrollment in Part A is complete, with interim results showing promise. Full data is expected in Q1 2027. The company also outlined plans for Part B expansion and broader applications for Annamycin.
Moleculin Biotech, Inc. (MBRX) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Moleculin Announces Reverse Stock Split HOUSTON, October 16, 2026 — Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that it filed an amendment to its amended and restated certificate of incorporation with the Secretary of Stat
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning MBRX (Moleculin Biotech, Inc.). Coverage has skewed bullish: 3 bullish, 2 neutral, and 0 bearish.
Recent MBRX coverage spans financial news, corporate actions and technology.
Positive trial progress should support further upside, especially if interim data are strong.
Positive trial progress suggests potential upside for the stock.
The reverse split will consolidate shares, likely causing short‑term price volatility and potential upward pressure as the share count shrinks.
The reverse split and immediate sell‑off suggest short‑term downward pressure.
The filing provides no new material information; market impact is expected to be neutral.
AlphAI scores every news story that mentions MBRX with an AI model for sentiment and relevance, and aggregates insider trades from Moleculin Biotech, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Myriad Genetics (MYGN) surged 40% after agreeing to sell its Prenatal Health business to Labcorp for $210M. Moleculin Biotech (MBRX) rose 15% on AML trial progress. Femasys (FEMY) and Revolution Medicines (RVMD) each gained 7% on commercial and clinical developments.
2 min readMoleculin Biotech (MBRX) released a CEO Corner segment discussing progress in its Phase 2/3 MIRACLE trial for Annamycin in treating relapsed or refractory AML. Enrollment in Part A is complete, with interim results showing promise. Full data is expected in Q1 2027. The company also outlined plans for Part B expansion and broader applications for Annamycin.
2 min readMoleculin Biotech, Inc. (MBRX) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Moleculin Announces Reverse Stock Split HOUSTON, October 16, 2026 — Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that it filed an amendment to its amended and restated certificate of incorporation with the Secretary of Stat
2 min readMoleculin Biotech (MBRX) announced a 1-for-20 reverse stock split, effective October 20, 2026. The company's shares fell over 16% in pre-market trading.
1 min readMoleculin Biotech, Inc. (MBRX) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1
1 min readMoleculin Biotech, Inc. (MBRX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As reported below under Item 5.07 of this Current Report, Moleculin Biotech, Inc. (the “Company”) held its scheduled 2026 A
1 min readMoleculin Biotech (MBRX) completed Part A enrollment in its Phase 2/3 MIRACLE trial for relapsed AML, with 89 participants. The trial evaluates Annamycin plus cytarabine. Results are expected in Q1 2027. No cardiotoxicity observed. MBRX stock is currently at $0.56.
2 min readMoleculin Biotech, Inc. (MBRX) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout – Rapid completion of Part A enrollment underscores strong operational execution and investigator engagement in relapsed or refracto
2 min readMoleculin Biotech (MBRX) published cardiac safety findings for Annamycin, showing no evidence of cardiotoxicity in 90 patients across five trials. Mean LVEF remained stable, and no relationship was found between cumulative Annamycin exposure and LVEF changes. The analysis supports continued clinical evaluation of Annamycin, which is being studied in the MIRACLE trial for relapsed or refractory AML. MBRX stock closed at $0.60, up 6.12%, and is currently down 1.26% in pre-market trading.
2 min readMoleculin Biotech, Inc. (MBRX) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine – Pooled analysis of five clinical trials found no clinical or subclinical evidence of cardiotoxicity at cumulative doses exceeding tradition
2 min read